» Articles » PMID: 35743021

Effective Natural Killer Cell Degranulation Is an Essential Key in COVID-19 Evolution

Abstract

NK degranulation plays an important role in the cytotoxic activity of innate immunity in the clearance of intracellular infections and is an important factor in the outcome of the disease. This work has studied NK degranulation and innate immunological profiles and functionalities in COVID-19 patients and its association with the severity of the disease. A prospective observational study with 99 COVID-19 patients was conducted. Patients were grouped according to hospital requirements and severity. Innate immune cell subpopulations and functionalities were analyzed. The profile and functionality of innate immune cells differ between healthy controls and severe patients; CD56dim NK cells increased and MAIT cells and NK degranulation rates decreased in the COVID-19 subjects. Higher degranulation rates were observed in the non-severe patients and in the healthy controls compared to the severe patients. Benign forms of the disease had a higher granzymeA/granzymeB ratio than complex forms. In a multivariate analysis, the degranulation capacity resulted in a protective factor against severe forms of the disease (OR: 0.86), whereas the permanent expression of NKG2D in NKT cells was an independent risk factor (OR: 3.81; AUC: 0.84). In conclusion, a prompt and efficient degranulation functionality in the early stages of infection could be used as a tool to identify patients who will have a better evolution.

Citing Articles

Immune dysregulation is an important factor in the underlying complications in Influenza infection. ApoH, IL-8 and IL-15 as markers of prognosis.

Garcinuno S, Lalueza A, Gil-Etayo F, Diaz-Simon R, Lizasoain I, Moraga A Front Immunol. 2024; 15:1443096.

PMID: 39176097 PMC: 11339618. DOI: 10.3389/fimmu.2024.1443096.


Recent Progress in Research on COVID-19 Pathophysiology: Biomarkers, Repurposed Drugs, Viral Invasiveness, SARS-CoV-2 Genetic Diversity, the Crystal Structure of Viral Proteins, and the Molecular and Cellular Outcomes of COVID-19.

Kubiak J, Kloc M Int J Mol Sci. 2022; 23(22).

PMID: 36430672 PMC: 9698337. DOI: 10.3390/ijms232214194.


Dynamic Evaluation of Natural Killer Cells Subpopulations in COVID-19 Patients.

Hutanu A, Manu D, Gabor M, Vasiesiu A, Andrejkovits A, Dobreanu M Int J Mol Sci. 2022; 23(19).

PMID: 36233174 PMC: 9569797. DOI: 10.3390/ijms231911875.

References
1.
Lee J, Park S, Kim T, Lee D, Kim D . Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study. Cancers (Basel). 2021; 13(3). PMC: 7865511. DOI: 10.3390/cancers13030471. View

2.
Bohn M, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K . Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression. Physiology (Bethesda). 2020; 35(5):288-301. PMC: 7426542. DOI: 10.1152/physiol.00019.2020. View

3.
Wilson J, Prow N, Schroder W, Ellis J, Cumming H, Gearing L . RNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammation. PLoS Pathog. 2017; 13(2):e1006155. PMC: 5312928. DOI: 10.1371/journal.ppat.1006155. View

4.
Vigon L, Fuertes D, Garcia-Perez J, Torres M, Rodriguez-Mora S, Mateos E . Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity. Front Immunol. 2021; 12:665329. PMC: 8187764. DOI: 10.3389/fimmu.2021.665329. View

5.
Gil-Etayo F, Garcinuno S, Utrero-Rico A, Cabrera-Marante O, Arroyo-Sanchez D, Mancebo E . An Early Th1 Response Is a Key Factor for a Favorable COVID-19 Evolution. Biomedicines. 2022; 10(2). PMC: 8869678. DOI: 10.3390/biomedicines10020296. View